Why the study?
Does chronic kidney disease stage affect the diuretic response to tolvaptan in patients with acute decompensated heart failure?
Does chronic kidney disease stage affect the diuretic response to tolvaptan in patients with acute decompensated heart failure?
In patients with acute decompensated heart failure, the diuretic efficacy of tolvaptan diminishes with advancing chronic kidney disease, though it appears safe without causing worsening renal function.
Answers are grounded in this paper and cite their sources.
Suggests tolvaptan efficacy wanes in advanced CKD despite apparent safety.
AIM: This study investigated the relationship between the initial diuretic response to tolvaptan and clinical predictors for tolvaptan responders in patients with acute decompensated heart failure (ADHF). METHODS AND RESULTS: Patients (153) with ADHF (clinical scenario 2 or 3 with signs of fluid retention) who were administered tolvaptan were enrolled. Tolvaptan (15 or 7.5 mg) was administered for at least 7 days to those patients in whom fluid retention was observed even after standard treatment. The maximum urine volume immediately after tolvaptan administration showed good correlations with the ejection fraction and estimated glomerular filtration rate that were independent predictors of the urine volume (UV) responders (≥1500 mL increase in urine volume). The diuretic response (in terms of maximum diuresis) diminished with advancing chronic kidney disease (CKD) stage and concomitant deterioration of the renal function. Furthermore, advanced CKD was a significant negative predictor for the body weight (BW) responders (2.0% decrease in the body weight within 1 week after starting tolvaptan). As compared with non-CKD, the presence of advanced CKD predicts poor diuretic response for both UV and BW responders. CONCLUSIONS: The diuretic response following tolvaptan administration gradually diminished with progressive deterioration of the CKD stage. Worsening renal function was not observed. Tolvaptan is effective in treating CS2 or CS3 ADHF patients who present fluid retention and congestion, suggesting its potential efficacy for fluid management in the ADHF patients with CKD without worsening the renal function.
No takes yet. Share an insight, caveat, or question.
Ikeda et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: